Oct.04.2021
R & D

European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma

 This material is intended to notify the press release issued on October 1 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.